Navigation Links
Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
Date:11/27/2007

BRISBANE, Australia, Nov. 27 /PRNewswire/ -- Xenome Ltd, a specialist biopharmaceutical company developing novel peptide drugs, announced today that it has successfully raised US$10M of equity finance. The syndicated funding round includes continuing support from Xenome's major investor, Queensland BioCapital Funds (QBF), for $2.7M, significant equity funding of $5m from Amylin Pharmaceuticals Inc, a top tier USA biotechnology company headquartered in San Diego, California, and $2.3M from Innovis Investment Partners (Innovis).

The combined investment will enable Xenome to continue the execution of its operational plan which includes:
- Implementation of a Joint Xenome-Amylin Research Collaboration

involving drug discovery of new compounds from Xenome's unique

peptide library using Amylin's assay technologies in the fields of

metabolic and musculoskeletal diseases;

- Expansion of the Phase 2 clinical development of Xenome's most

advanced and promising drug candidate, Xen2174, for the treatment of

acute and chronic intractable pain and;

- Furthering the development of Xenome's current drug candidate

pipeline.

"The opportunity to make two major announcements on the same day does not come around very often, so it is satisfying to be able to announce this new syndicated investment by QBF, Amylin and Innovis together with the execution of the separate Joint Xenome-Amylin Research Collaboration. The Company recognizes QBF's sustained support and belief in Xenome at a time when biotech funding comes at a premium. At the same time we welcome new substantial shareholders Amylin and Innovis Ltd. to the Company's share register." said Xenome CEO, Lewis Lee.

"The equity investment integrated with the extensive Xenome-Amylin Joint Research Collaboration provides a tremendous validation of the Company's peptide drug discovery platform and will facilitate Xenome's ability to rapidly generate novel lead molecules for key therapeutic targets." commented Cherrell Hirst, QBF CEO and Innovis General Partner.

Xenome information:

Lewis Lee

Director & CEO

Xenome Ltd

Tel: +61 7 3720 8055

E-mail: lewis.lee@xenome.com

Website: http://www.xenome.com

QBF and Innovis Information:

Cherrell Hirst MD (CEO)

QBF Pty Ltd.

Tel: +61 7 3009 6850

E-mail: c.hirst@qbf.qic.com

Website: http://www.qic.com

About Xenome

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

http://www.xenome.com

About QBF

Queensland BioCapital Funds Pty Ltd (QBF) is a $100 million closed end venture capital fund that seeks to invest in listed or unlisted companies in the human biosciences sector, in particular, pharmaceuticals, medical devices, consumer healthcare products and diagnostics. It is a wholly owned subsidiary of the Queensland Investment Corporation (QIC), one of Australia's largest institutional fund managers with over $50 billion in funds invested and owned by the Queensland Government, but with a Board and staff drawn from the private sector. QBF was established in October 2002 to assist QIC in its role as trustee and manager of the fund by identifying, validating and managing investment opportunities. QBF is actively involved in its investee companies, typically holding a significant equity position for several years in the form of preference shares with specified rights.

http://www.qbf.qic.com/

About Innovis

Innovis Investment Partners Australia LP is a venture capital fund focusing on private and micro-cap public companies in Biotechnology, Pharmaceuticals and Healthcare.


'/>"/>
SOURCE Xenome Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... fiscal year ended September 30, 2016. ... , , SQI ... company that develops and commercializes proprietary technologies and products for advanced ... revenues of $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... platforms, announced today that the company has engaged in a collaborative research partnership ... (MRDA) with the CSU Office of the Vice President for Research. This agreement ...
(Date:12/6/2016)... , Dec. 6, 2016  SRI International ... $150 million from the National Institutes of Health,s ... the Division of AIDS (NIAID-DAIDS) to support the ... non-vaccine pre-exposure (PreP) agents. Under the seven-year contract, ... product development services for candidate HIV-prevention products that ...
(Date:12/5/2016)... Atlanta, Georgia (PRWEB) , ... December 05, 2016 ... ... hydrophobic, lignin-coated nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition ... nanocellulose. There are also claims directed to combination with polymers, carbon fibers, ...
Breaking Biology Technology:
(Date:11/22/2016)... PUNE, India , November 22, 2016 According ... (Single-Factor: (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware ... to 2022", published by MarketsandMarkets, the market is expected to grow from ... at a CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... 17, 2016  AIC announces that it has just released a new white paper ... high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or HPC ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):